1stOncology™: Cancer Intelligence Service – Page 99 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Autolus Therapeutics to Participate in Upcoming Investor Conferences

On April 7, 2026 Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, reported that the Company will participate in two upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

25th Annual Needham Virtual Healthcare Conference
Date and time: April 13, 2028; 10:15am EDT / 3:15pm BST
Presenter: Chief Executive Officer Dr. Christian Itin

A webcast of the presentation will be available on the "Events" page in the "Investor Relations & Media" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Van Lanschot Kempen Life Sciences Conference
Management to host investor meetings
Date: April 16, 2026
Location: Amsterdam

(Press release, Autolus, APR 7, 2026, View Source [SID1234664227])

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

On April 7, 2026 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, reported that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time.

A live webcast of the presentation can be accessed through the Investors section of the Company’s website at www.lyell.com. A replay of the webcast will be available on the Company’s website following the presentation date.

(Press release, Lyell Immunopharma, APR 7, 2026, View Source [SID1234664226])

Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology

On April 7, 2026 Pluristyx, a leader in advanced induced pluripotent stem cell (iPSC)-based solutions, reported expansion of its intellectual property portfolio with a U.S. patent allowance for claims covering cells expressing autoimmune-associated self-antigens coupled with its exclusive induced Allogeneic Cell Tolerance (iACT Stealth) technology for "cell cloaking".

The newly allowed patent claims are specifically drawn to the use of iACT in the treatment of autoimmune diseases. With this technology Pluristyx can combine a genetic engineering package integrating iACT Stealth with self-antigen technology, and "train" a patient’s own immune system. This innovative approach allows for a precise, desired immune response to a self-antigen without dangerous "off-target" effects or using traditional debilitating systemic immune suppression.

This patent marks a pivotal shift in the use of cell therapy beyond oncology. By pairing iACT Stealth cloaking with specific self-antigens, Pluristyx is enabling development of "tolerogenic" cell therapies. Unlike traditional methods that broadly suppress the immune system, leaving patients vulnerable to infections, this technology allows engineered cells to persist in the body and specifically retrain the immune system to stop attacking itself. This represents a new frontier in "living medicine," where engineered iPSC-derived cells act as a localized, intelligent platform for long-term autoimmune remission.

iACT Stealth is designed to work in tandem with Pluristyx’s FailSafe technology. FailSafe’s drug-inducible safety feature acts as a genetic "kill switch," allowing for the selective removal of any proliferating cells to ensure patient safety and is the only commercially-available safety switch technology.

"This addition to our patent portfolio furthers our commitment to advancing regenerative, living-medicine therapies, now in the autoimmune field," said Kaye Reiter, PhD, JD, Pluristyx Chief Legal Officer. "We continue to expand our exclusive intellectual property portfolio of combined iPSC, FailSafe, and iACT Stealth technologies that are setting the standard for functionality, safety, and scalability".

Pluristyx’s full suite of technologies, including iACT Stealth, FailSafe, and proprietary mRNA-based iPSC reprogramming technology, is available for immediate adoption through a streamlined research evaluation and commercial licensing model. This provides partners today with a powerful, clinical-grade foundation to bring tomorrow’s next-generation living medicines to market.

(Press release, Pluristyx, APR 7, 2026, View Source [SID1234664225])

Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

On April 7, 2026 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, reported it will present new data at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) annual meeting in Boston, Massachusetts on May 14, 2026. The Company will present data on its RedTail platform.

RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at the ASGCT (Free ASGCT Whitepaper) meeting by Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi, will showcase the ability of the RedTail extracellular enveloped and CD55-overexpressing virus (EEV) to avoid immune clearance, replicate only in target cells, and deliver high concentrations of genetic medicine to sites of disease.

CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), a known T- and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026. Additionally, Calidi is expanding the RedTail platform to enable in situ expression of T-cell engagers (TCEs) in solid tumors, including in combination with T-cell activating payloads such as IL15 SA. This strategy is intended to support localized T-cell- engagement within the tumor microenvironment following systemic administration.

"The data we will present at ASGCT (Free ASGCT Whitepaper) highlight the advances we have made with our novel approach to the targeted, systemic delivery of genetic medicines" said Dr. Santidrian. "In our preclinical and syngeneic models, we are seeing profound biology driven by targeted genetic expression with RedTail candidates."

"We continue to advance the RedTail platform with an IND filing expected this year for CLD-401" said Eric Poma, PhD, Chief Executive Officer of Calidi. "We continue to expand what the RedTail platform can do with new payload, a novel approach to in situ T-cell engagers, and ongoing lead discovery in indications outside of oncology."

The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

(Press release, Calidi Biotherapeutics, APR 7, 2026, View Source [SID1234664224])

Recursion to Participate in Upcoming Investor Conferences

On April 7, 2026 Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, reported its participation in the following upcoming investor conferences:

25th Annual Needham Virtual Healthcare Conference – Monday, April 13, 2026
Bank of America Health Care Conference 2026 – Tuesday, May 12, 2026

Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.

(Press release, Recursion Pharmaceuticals, APR 7, 2026, View Source [SID1234664223])